The therapeutic development of a clinical NR1H3 antisense oligonucleotide to reprogram microglia into a neuroprotective state in ALS and FTD
Active Grant Awarded
- Award ID
- R44NS143633
- Recipient
-
Modulo Bio, Inc. UEI U1TNJGPGNHA9
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $847,695
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 8% complete
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke, awarded Modulo Bio, Inc. $847,695 on September 19, 2026, under Grant R44NS143633, funded through the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The assistance type is a grant.
The funded project develops lead and backup antisense oligonucleotides (ASOs) targeting NR1H3, a microglial transcriptional regulator, for direct administration into the central nervous system as a therapeutic for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). The work will characterize the therapeutic window, PD biomarkers, and safety profile of these ASOs, and identify a development candidate suitable for IND-enabling studies and progression into clinical trials. Performance is in San Diego, California (ZIP 92121), with an ultimate completion date of August 31, 2028.
Description
- Abstract
- /summary: background and rationale: our long-term goal is to develop an antisense oligonucleotide (ASO) therapeutic targeting NR1H3 as a treatment for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD), both of which currently have limited disease-modifying therapies. Although genes selectively expressed in microglia (MG) harbor some of the strongest risk alleles for ALS/FTD, IT remains unclear in which contexts MG drive or rescue neurodegeneration. Thus, there is a pressing need to understand how MG modulate neurodegeneration and leverage this knowledge for therapeutic benefit. We developed an induced pluripotent stem cell (IPSC) TRI-culture model of ALS/FTD patient IPSC-derived microglia (IMG), motor neurons (INS) and astrocytes, and identified a previously unreported neuroprotective cell state of microglia in the context of C9ORF72 biology. Our data suggest that knocking down microglial NR1H3, a transcriptional regulator, shifts ALS/FTD microglia from a neurotoxic state into a neuroprotective state characterized by low-level surface expression of CSF1R. This state rescues neurodegeneration in C9ORF72 and sporadic forms of ALS/FTD in IPSC and mouse models. Small molecule modulators of lxrɑ (NR1H3) exist but these compounds have limited brain penetrance and off-target effects. Furthermore, most compounds agonize lxrɑ; while we have in vivo data showing that partial inhibition will be beneficial and is likely disease-context specific. We are proposing to develop a lead and backup asos specific for NR1H3, suitable for direct administration into the CNS. In the proposed study, we will characterize the therapeutic window, PD biomarkers, and safety profile of these asos. We will identify a development candidate suitable for progression through IND enabling studies and into clinical trials. Objective/hypothesis: our central hypothesis is that NR1H3 knockdown can attenuate neurodegeneration by shifting neurotoxic MG into a neuroprotective state. We will test this hypothesis in ALS/FTD ipscs and animal models. Specific aims: in this grant, we propose to validate and characterize a potent and tolerable lead and backup candidate asos through assessing toxicity/tolerability, defining a therapeutic window, and characterizing an 8 week dose range finding non-GLP toxicology profile. We will also define the changes in MG that correlate with neuroprotection to identify a treatment regimen and biomarkers for further clinical development. Impact: if successful, we will advance our NR1H3 ASO into IND-enabling studies. Innovation: the following are innovative aspects of the study that will provide key advances: 1) characterization of novel NR1H3 asos and biology of NR1H3 in the CNS, 2) use of patient IPSC-derived triculture and validation in mouse and human tissues to validate NR1H3 ASO, 3) reprogramming the MG state by NR1H3 knockdown is a novel approach, and 4) identification of biomarkers for patient selection and treatment monitoring will streamline the clinical path.
Quick answers
Who received award R44NS143633?
R44NS143633 was awarded to Modulo Bio, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 19, 2026.
How much is award R44NS143633 worth?
$847,695 has been obligated on R44NS143633.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award